Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice

Since smallpox eradication by the WHO during the 1980s, potency of new vaccines is compared to vaccines that were used during the eradication campaign. In this work we characterize the tail scarification technique in mice as a model for scarification in humans. Similar to humans, mice develop '' clinical take '' which is dependent on the vaccination dose. Appearance of anti-Vaccinia IgM is followed by IgG antibodies 10 days post scarification and lasting more then 11/2 years. Mice with '' clinical take '' are 100% protected against lethal respiratory challenge (100LD(50)) of Vaccinia WR indicating that the '' clinical take '' can serve as a correlate of protective immunity. Reducing the vaccination dose and using Cowpox virus as a more virulent strain, enabled us to draw the limit of the vaccine potency in mice. Similar to humans, in revaccinated mice the development of '' clinical take '' was inversely correlated to the level of pre-existing antibodies. These results indicate that tail scarification of mice can be used as a model for evaluation of smallpox vaccines. High correlation between '' clinical take '' and protective immunity allows the use of visual inspection to evaluate vaccine potency. (c) 2007 Elsevier Ltd. All rights reserved.